Contact Us
United States - English
China - 简体中文China - 繁體中文Germany – DeutschJapan - 日本語Switzerland - FrançaisUnited States - English

WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates

Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results.
Filter By
All Years

2021/12/09

WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

SHANGHAI, December 8, 2021 -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global research & consulting firm that helps clients accelerate growth. This marks the fifth consecutive year that WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.

Read more

2021/10/29

WuXi AppTec Reports Strong Third-Quarter 2021 Results

Revenue Up 30.6% Year-Over-Year to RMB5,985 Million Net Profit Attributable to Owners of the Company Up 36.2% Year-Over-Year to RMB887 Million Diluted EPS Up 30.4% Year-Over-Year to RMB0.30 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 37.8% Year-Over-Year to RMB1,358 Million Adjusted Non-IFRS Diluted EPS Up 39.4% Year-Over-Year to RMB0.46

Read more

2021/09/05

WuXi AppTec Receives AA ESG Rating from MSCI

Shanghai, September 5, 2021 – WuXi AppTec (“the Company”) is pleased to announce that Morgan Stanley Capital International ("MSCI”) has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of “corporate governance” and “product safety and quality”. This new rating reflects WuXi AppTec’s commitment to incorporating environmental and social responsibilities into the company’s business strategies and operations.

Read more

2021/08/12

WuXi AppTec Reports Strong 2021 Interim Results

Revenue Up 45.7% Year-Over-Year to RMB10,537 Million Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-Year to RMB2,448 Million Adjusted Non-IFRS Diluted EPS Up 58.5% Year-Over-Year to RMB0.84

Read more

2021/08/03

WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

State-of-the-art facility significantly enhances WuXi STA's drug product capacity in Europe while better enabling global customers

Read more